About the webinar:
Murine Fc gamma receptors (FcγRs) in preclinical models pose significant challenges in the evaluation of antibody-based therapies, often leading to misleading outcomes that can derail drug discovery. The novel FcResolv® NOG model portfolio is designed to target the knockout of these receptors to eliminate significant confounding variables and improve the accuracy of antibody-based drug studies.
Discover how super immunodeficient FcResolv® NOG mice are offering researchers greater confidence and more translatable data while utilizing fewer resources. In this webinar, Dr. Ditte Olsen dives into the FcResolv® NOG portfolio, including the super immunodeficient FcResolv® NOG strain, strains that express human cytokines on the FcResolv® NOG background in order to support certain human immune cells, and several humanized immune system (HIS) FcResolv® NOG models. Get insight into the utility of these innovative models for research involving antibody-based therapeutics.
Watch this webinar to:
- Discover how the FcResolv® NOG Portfolio extends the utility of the widely used super immunodeficient CIEA NOG mouse® by eliminating murine Fc gamma receptors known to derail antibody-based drug discovery
- Understand how researchers avoid wasteful investments based on false positives or missing out on a promising candidate due to false negatives
- Learn how FcResolv® NOG mice are suited to a range of applications, particularly tumor xenografts, cell and tissue engraftment, and drug efficacy studies with antibody-based therapeutics
- Get insight into the newest additions to the FcResolv® NOG portfolio, including a humanized immune system (HIS) model supporting human myeloid and lymphoid cells - the FcResolv® huNOG-EXL
